The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients
Abstract
BACKGROUND: One of the most troublesome features of atopic dermatitis (AD) is its chronic relapsing nature, and there is a lack of published evidence on the best treatment strategy for long-term management of the disease. OBJECTIVE: To compare an intermittent dosing regimen of fluticasone propionate (FP) cream 0.05% (twice per week) with its vehicle base in reducing the risk of relapse when added to regular daily emollient in adult and paediatric subjects with stabilized AD. METHODS: Subjects (aged 3 months to 65 years) with moderate or severe AD were enrolled into an open-label Stabilization Phase of up to 4 weeks on daily emollients plus FP twice daily. Those subjects who achieved 'treatment success' (Global Assessment Score </= 2, erythema, pruritus, and papulation/induration/oedema scores </= 1) entered the double-blind Maintenance Phase. They continued with regular emollients and were randomized at a 2 : 1 ratio to either intermittent FP or vehicle, once daily 4 days per week for 4 weeks followed by once daily 2 days per week for 16 weeks. Subjects who relapsed on intermittent FP were discontinued from the study. Those who did not relapse continued for an additional 24 weeks on intermittent dosing for safety monitoring. RESULTS: A total of 372 (247 paediatric, 125 adult) subjects were enrolled into the Stabilization Phase. Of these, 348 (231 children, 117 adults) were randomized into the Maintenance Phase. Analysis of the primary efficacy parameter showed that subjects receiving intermittent FP cream (twice per week), in addition to regular daily emollients in the Maintenance Phase, were 7.7 times less likely to have an AD relapse than subjects receiving intermittent vehicle cream/emollients [Mantel-Haenszel (MH) estimate of the odds ratio, 95% confidence interval (CI) 4.6, 12.8; P < 0.001]. Paediatric subjects were 8.1 times less likely to have an AD relapse (95% CI 4.3, 15.2; P < 0.001) and adult subjects were 7.0 times less likely to have an AD relapse (95% CI 3.0, 16.7; P < 0.001). For subjects receiving intermittent FP cream/emollient, the median time to relapse could not be estimated as the majority remained controlled at 20 weeks. For those receiving intermittent vehicle/emollient, the median time to relapse was 4.7 weeks. For paediatric and adult groups, this was 5.1 and 4.1 weeks, respectively. Median exposure to FP for all subjects was 337 days. There was only one study drug-related adverse event (acne) and there were no reports of skin thinning or atrophy associated with the use of FP cream in paediatric or adult subjects. CONCLUSIONS: In paediatric and adult subjects, once stabilized with regular FP treatment, the risk of relapse of AD can be significantly reduced by extended intermittent dosing with FP cream in addition to regular emollient therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Self-citationSystematic review of treatments for atopic eczema.
Hoare, Po, L. W., & Williams (2000) · Health Technology Assessment · doi:10.3310/hta4370 · Cited by 794
Topical corticosteroid phobia in patients with atopic eczema: CORTICOSTEROID PHOBIA IN ATOPIC ECZEMA
Charman, C. R., Morris, A. D., & Williams, H. C. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03473.x · Cited by 590
The prevalence of childhood atopic eczema in a general population
Kay, J., Gawkrodger, D. J., Mortimer, M. J., & Jaron, A. G. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(94)70004-4 · Cited by 496
The family impact of childhood atopic dermatitis: The Dermatitis Family Impact Questionnaire
Lawson, Lewis-Jones, Finlay, Reid, & Owens (1998) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1998.02034.x · Cited by 434
The prevalence of atopic dermatitis in Oregon schoolchildren
Laughter, D., Istvan, J. A., Tofte, S. J., & Hanifin, J. M. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.107773 · Cited by 367
Self-citationThe occurrence of atopic dermatitis in North Europe: An international questionnaire study
Larsen, F. S., Diepgen, T., & Svensson, Å. (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90009-2 · Cited by 340
The human pharmacology of fluticasone propionate
Harding, S. M. (1990) · Respiratory Medicine · doi:10.1016/s0954-6111(08)80004-2 · Cited by 313
Essential Aspects of Atopic Dermatitis
Rajka, G. (1989) · Springer eBooks · doi:10.1007/978-3-642-74766-3 · Cited by 242
Meer, V. D., Glazenburg, Mulder, Eggink, Coenraads, & ON BEHALF OF THE NETHERLANDS ADULT ATOPIC DERMATITIS STUDY GROUP (1999) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1999.02893.x · Cited by 187
Sugiura, H. (1998) · Acta Dermato Venereologica · doi:10.1080/000155598441891 · Cited by 149
The relation of stress and family environment to atopic dermatitis symptoms in children
Gil, K. M., Keefe, F. J., Sampson, H. A., McCaskill, C. C., Rodin, J., & Crisson, J. E. (1987) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(87)90016-x · Cited by 129
Atopic dermatitis in children: Who cares? Who pays?
Lapidus, C. S., Schwarz, D. F., & Honig, P. J. (1993) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(93)70096-c · Cited by 124
TURPEINEN, M., SALO, O. P., & LEISTI, S. (1986) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1986.tb06242.x · Cited by 104
Friedlander, S. F., Hebert, A. A., & Allen, D. B. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.118337 · Cited by 89
Managing Pediatric Atopic Dermatitis
Raimer, S. (2000) · Clinical Pediatrics · doi:10.1177/000992280003900101 · Cited by 84
Cited by
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., Berger, T. G., Bergman, J. N., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.010 · Cited by 1,277
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Williams, H. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042803 · Cited by 523
Metadata
- Authors
- Hanifin, J., Gupta, A. K., & Rajagopalan, R.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-09
- Volume
- 147
- Issue
- 3
- Pages
- 528-537
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W1965953118
- Cited by
- 264
- References
- 18
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.